<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883203</url>
  </required_header>
  <id_info>
    <org_study_id>VITD COVIDMonastir</org_study_id>
    <nct_id>NCT04883203</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D Supplementation on COVID-19 Recovery</brief_title>
  <acronym>COVID-VITD</acronym>
  <official_title>The Effect of Vitamin D Supplementation on Recovery Delays for Non Severe COVID-19 Cases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Monastir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loussaief Chawki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nissaf Ben Alaya</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cyrine Ben Nasrallah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manel Ben Belgacem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hela Abroug</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imen Zemni</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manel Ben fredj</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wafa Dhouib</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Monastir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 caused by SARS-CoV-2 has transmitted quickly as a global public health&#xD;
      emergency. The median duration for Sars-CoV-2 carrying in COVID-19 patients was 20 days (IQR&#xD;
      16-28) What is the role of vitamin D supplementation on the recovery time of asymptomatic and&#xD;
      pauci-symptomatic COVID-19 subjects? the intervention group will have vitamin D&#xD;
      supplementation (200,000 IU / 1 ml of Cholecalciferol (1 ml) Oral form). Control group will&#xD;
      have a placebo treatment (physiological saline).&#xD;
&#xD;
      the negative RT-PCR date will be compared in the two groups&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction In 2020 The world is incurring coronavirus pandemic. The epidemic of the new&#xD;
      coronavirus started in Wuhan, China, in late 2019, originally called 2019-nCoV and then&#xD;
      COVID-19 by the World Health Organization in February 2020.&#xD;
&#xD;
      COVID-19 presented a heavy health systems burden having caused more than 170,000 deaths&#xD;
      worldwide as of April 20, 2020. However, the treatment protocols for this infection remain&#xD;
      controversial. It is the subject of several ongoing studies.&#xD;
&#xD;
      The use of vitamin D as a strategy to reduce the frequency and severity of respiratory&#xD;
      infections and in particular COVID-19 must be seriously considered.&#xD;
&#xD;
      Several studies have studied the role of vitamin D in reducing the risk of viral infections.&#xD;
      Indeed, vitamin D supplementation could be a useful measure in improving the immune response&#xD;
      of subjects affected by the new coronavirus. This, taking into account the high prevalence of&#xD;
      vitamin D deficiency in our country.&#xD;
&#xD;
      The beneficial effects of vitamin D on protective immunity is partly due to innate immune&#xD;
      system action. It reduces the cytokine storm induced by the innate immune system, by&#xD;
      decreasing the expression of pro-inflammatory cytokines and increasing that of&#xD;
      anti-inflammatory cytokines. Vitamin D played a major role in the modulation of adaptive&#xD;
      immunity. However, evidence on the effectiveness of vitamin D in improving the immune&#xD;
      response of confirmed COVID-19 remains lacking.&#xD;
&#xD;
      The prolonged duration of the disease may increase the likelihood of transmission. Indeed,&#xD;
      the R0 depends on three factors including the contact rate between individuals in the&#xD;
      population, the probability of transmission of the infection during contact and the duration&#xD;
      of infectiousness. The COVID-19 caused by SARS-CoV-2 has transmitted quickly as a global&#xD;
      public health emergency. The median duration for Sars-CoV-2 carrying in COVID-19 patients was&#xD;
      20 days (IQR 16-28)(9).&#xD;
&#xD;
        1. Research question:&#xD;
&#xD;
           What is the role of vitamin D supplementation on the recovery time of asymptomatic and&#xD;
           pauci-symptomatic COVID-19 subjects?&#xD;
&#xD;
        2. Objectives of the study:&#xD;
&#xD;
           To assess the effect of vitamin D supplementation on the duration of carriage of the&#xD;
           COVID-19 virus in patients with SARS Cov2 with a positive control RT-PCR on day 14 of&#xD;
           the date of confirmation of the disease.&#xD;
&#xD;
        3. Type of study:&#xD;
&#xD;
      This is a randomized clinical trial without the patient's knowledge in subjects diagnosed&#xD;
      with COVID-19.&#xD;
&#xD;
      B. Method:&#xD;
&#xD;
        1. Study setting: this study will be carried out in the governorate of Monastir in the&#xD;
           collective isolation center&#xD;
&#xD;
        2. Eligibility criteria: patients with SARS Cov2 and having a positive RT-PCR at control in&#xD;
&#xD;
             -  14 days from confirmation of infection for asymptomatic subjects and&#xD;
&#xD;
             -  7 days after the disappearance of symptoms for pauci-symptomatic subjects.&#xD;
                Non-inclusion criteria: Pregnant women and children under the age of 18 will not be&#xD;
                included.&#xD;
&#xD;
        3. Intervention: the intervention group will have vitamin D supplementation (200,000 IU / 1&#xD;
           mL of Cholecalciferol (1 ml) Oral form). Control group will have a placebo treatment&#xD;
           (physiological saline).&#xD;
&#xD;
        4. Output: the negative RT-PCR date will be compared in the two groups.&#xD;
&#xD;
        5. Variables: we will study the socio-demographic characteristics (age, sex, level of&#xD;
           study) and the recovery dates (dates of confirmation samples, disappearance of symptoms&#xD;
           and control) the presence of hospitalization.&#xD;
&#xD;
        6. Sample size: for a gain of 07 days for healing, with 90% power and a 2-sided 0.05&#xD;
           significance level, 130 patients were required (65 in each group).&#xD;
&#xD;
      C. Allocation of interventions:&#xD;
&#xD;
      After a phone agreement, a doctor ensures the treatment distribution. D. Ethical&#xD;
      considerations This survey will be carried out respecting the research ethical&#xD;
      considerations: consent (free, informed, written, clear and loyal) anonymity;&#xD;
      confidentiality; protection and assistance.&#xD;
&#xD;
      E. Study budget The Monastir University Hospital of Monastir will fund study (buying Vit D).&#xD;
      F. Study schedule This interventional investigation will begin in July 2020. Patient&#xD;
      monitoring will be carried out until the recovery date. (2 negative RT-PCR tests).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2020</start_date>
  <completion_date type="Actual">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized clinical trial with 2 parallel arms and participant masking</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>the intervention group will have vitamin D supplementation (200,000 IU / 1 mL of Cholecalciferol (1 ml) Oral form).&#xD;
Control group will have a placebo treatment (physiological saline).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D supplementation and recovery delay in COVID-19 patients</measure>
    <time_frame>3 months</time_frame>
    <description>Delay between the first positive RT-PCR and the second negative RT-PCR</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>VITD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single vial of Cholecalciferol (1 ml) (200,000 IU / 1 m), Oral form,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single vial of physiological salin Oral form</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vit-D 0.2 MG/ML Oral Solution [Calcidol]</intervention_name>
    <description>ARM 1 : Cholecalciferol 200,000 IU / 1 mL .</description>
    <arm_group_label>VITD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiological Irrigating Solution</intervention_name>
    <description>ARM 2 : placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with COVID 19 and having a positive RT-PCR at control in&#xD;
&#xD;
               -  14 days from confirmation of infection for asymptomatic subjects and&#xD;
&#xD;
               -  7 days after the disappearance of symptoms for pauci-symptomatic subjects&#xD;
&#xD;
        Non inclusion Criteria: Pregnant women and children under the age of 18 will not be&#xD;
        included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asma Sriha Belguit</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <link>
    <url>https://www.nejm.org/doi/full/10.1056/nejmoa2001017</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Monastir</investigator_affiliation>
    <investigator_full_name>Sriha Belguith_asma</investigator_full_name>
    <investigator_title>Professor preventive medicine and epidemiology</investigator_title>
  </responsible_party>
  <keyword>COVID 19</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Plasma-lyte 148</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

